eyeforpharma Barcelona Conference, Expo & Awards 2019

eyeforpharma12 - 14 March 2019, Barcelona, Spain.
It's 2019, and it's time for something new. Attendance is ahead of expectations, eyeforpharma Barcelona is on track for over 1300 pharma decision makers from Sales, Marketing, Patient Engagement, Patient Advocacy, Medical Affairs, Digital, Market Access and RWE functions to fuse with health innovators, payers, patients, start-ups and cutting-edge tech.

On current projections, tickets will sell out this year. Ensure you have a place reserved at the only meeting where executives forge a new future for the pharma industry.

Medicine is just the beginning

Medicines are essential, yet they're rarely the entire solution. As we shift focus to outcomes, we need to be prepared to deliver value in whatever form is best for patients. The keynote sessions at eyeforpharma Barcelona will cover:
  • Value, driven.
    Change your mindset to reach beyond the incremental - and find bold solutions for real patients. Only then will outcomes be transformed.
  • Authenticity rules.
    Use greater patient insights to build trust with customers and fight for the best patient journey. Make education and credibility your mantra!
  • Tech is fundamental.
    See how digital ML & AI are delivering the data that rewrites your business plan, sets new standards and makes the connected future a reality.
  • Welcome new customers.
    Exceed elevated expectations by aligning to consumerisation - and setting new goals in wellbeing, prevention and regeneration.

New for 2019

The Innovation Stage

A showcase of bleeding-edge, industry-transforming science and new ideas which will open your eyes to the coming disruptions.

Real-World Evidence Europe Summit

For 2019 we've added our industry-leading Real-World Evidence Summit to the event to show the role RWE will play in the shift to value

The im-patient conference

Patient-focused conferences are usually designed by pharma. Until now! This time, patients have created the agenda and line-up.

Market Access Europe Summit

Market Access is vital for pharma's commercial success - that's why for 2019 it has been added as a key topic.

This is the world's biggest commercial pharma meeting and your opportunity to join 1300+ pharma leaders focused Sales, Marketing, Patient Engagement, Market Access, Medical Affairs and Real-World Evidence

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save €300 when you register here

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Lilly and Lycia Therapeutics enter into strategic …

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, devel...

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...